A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women.

Trial Profile

A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2013

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Cervical intraepithelial neoplasia; Genital warts; Human papillomavirus infections; Vaginal intraepithelial neoplasia; Vulvar intraepithelial neoplasia
  • Focus Adverse reactions
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 06 Jul 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 01 Mar 2008 Results have been reported
    • 26 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top